Personalized treatment approach for HER2-positive metastatic breast cancer
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02504-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Prashant Pandey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Precision Medicine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India.
- PSIT-Pranveer Singh Institute of Technology (Pharmacy), Kanpur, India.
- Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
- Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024). Personalized treatment approach for HER2-positive metastatic breast cancer. Medical Oncology. https://doi.org/10.1007/s12032-024-02504-4
Vancouver
Pandey P, Chaudhary R, Tripathi D, Lavudi K, Dua K, Weinfeld M, et al. Personalized treatment approach for HER2-positive metastatic breast cancer. Medical Oncology. 2024. doi:10.1007/s12032-024-02504-4
BibTeX
@article{Pandey2024,
author = {Pandey, Prashant and Chaudhary, Rishabh and Tripathi, Devika and Lavudi, Kousalya and Dua, Kamal and Weinfeld, Michael and Lavasanifar, Afsaneh and Rajinikanth, P S},
title = {Personalized treatment approach for HER2-positive metastatic breast cancer},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02504-4}
}
EUVIMED